Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Meningeal Neoplasms 1Meningeal Carcinomatosis 1Lymphoma 1Leukemia 1Central Nervous System Neoplasms 1

Interventions

Radiotherapy 83Temozolomide 78Filgrastim 34Carboplatin 33Vincristine 29Etoposide 26Cyclophosphamide 25Carmustine 25Irinotecan 23Chemotherapy, Adjuvant 23Cisplatin 21Peripheral Blood Stem Cell Transplantation 20Thiotepa 14Lomustine 14Granulocyte Colony-Stimulating Factor 13Surgical Procedures, Operative 12Procarbazine 12Bevacizumab 11Thalidomide 10O(6)-benzylguanine 10Drug Therapy 10etoposide phosphate 9Methotrexate 9Magnetic Resonance Spectroscopy 9Gene Expression Profiling 9Radiation 8Paclitaxel 8sargramostim 7Ifosfamide 7Everolimus 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Central Nervous System Neoplasms × mafosfamide × Clear all
NCT00031928 2015-04-30

Mafosfamide in Treating Patients With Progressive or Refractory Meningeal Tumors

National Cancer Institute (NCI)

Phase 1 Completed
3,000 enrolled
CNS

Central Nervous System Neoplasms, Meningeal Carcinomatosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡